InnovAge Holding to Pay $36 Million to Resolve Allegations of False Claims Act, State Law Violations — Update
By Kelly Cloonan
InnovAge Holding agreed to pay $36 million to resolve allegations that it violated federal and state laws by failing to provide medical services and referrals as quickly as necessary to address its senior patients' health conditions.
InnovAge receives Medicare and Medicaid funding to provide healthcare services to seniors at centers across several states. According to the Justice Department, the Denver-based company did not maintain sufficient specialist provider networks and often failed to timely schedule appointments or consultations for specialist medical care for its patients in areas like oncology, cardiology, surgery and neurology, for a period between 2016 and 2022.
As a result, it failed to keep up with the requirements of the dual Medicare-Medicaid program it provides those services under, violating the federal False Claims Act as well as state laws, the Department of Justice said.
The settlement is not a determination of liability.
A spokesperson for InnovAge said the company has worked closely with the Centers for Medicare and Medicaid Services and its state government partners while investing to strengthen its clinical operations, compliance infrastructure and care delivery capabilities.
"Resolving these historical allegations from 2016 to 2022, with no admission of wrongdoing, allows us to move forward with a continued focus on delivering high-quality, compassionate care to the frail seniors we serve," the spokesperson said.
With the settlement, InnovAge will pay about $25.7 million to the U.S. and a combined $10.3 million to Colorado, California, New Mexico and Virginia.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
November 17, 2026 13:49 ET (18:49 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?

